Correlation between weakness and axonal loss in patients with CMT1A

Area of Science:

• Neurology
• Genetics
• Biomedical Engineering

Background:

• Charcot-Marie Tooth (CMT) disease, particularly CMT1, is a chronic condition with poorly understood natural history over short periods.
• Evaluating clinical trials for CMT1 is challenging due to the limited understanding of disease progression.
• Schwann cell myelin gene expression abnormalities are the primary cause of CMT1.

Purpose of the Study:

• To develop and validate a protocol for measuring disability progression in CMT patients over several years.
• To investigate the correlation between clinical examination findings, strength, sensory loss, axonal loss, and demyelination in CMT1.
• To test the hypothesis that weakness in CMT1 is secondary to axonal loss.

Main Methods:

• Developed a novel protocol to assess disability progression in Charcot-Marie Tooth (CMT) patients.
• Utilized various modalities to measure patient strength, sensory loss, axonal loss, and demyelination.
• Compared these measurements to clinical examination findings to establish correlations.

Main Results:

• Patient weakness in CMT1 was found to correlate more strongly with secondary axonal loss.
• The correlation between weakness and demyelination was less pronounced.
• The developed protocol effectively measured disease progression and correlated with clinical findings.

Conclusions:

• Weakness in Charcot-Marie Tooth type 1 (CMT1) is primarily associated with secondary axonal loss, not the primary demyelination.
• The developed protocol provides a reliable method for tracking CMT1 progression and evaluating clinical trial efficacy.
• Understanding the relationship between axonal loss and weakness is crucial for future CMT therapeutic strategies.